<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914119</url>
  </required_header>
  <id_info>
    <org_study_id>JLT-NM4</org_study_id>
    <nct_id>NCT02914119</nct_id>
  </id_info>
  <brief_title>Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals</brief_title>
  <official_title>Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jakob Louis Thomsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To explore

        -  the frequency of use of objective neuromuscular monitoring for assessment of depth of
           neuromuscular blockade in general anaesthesia

        -  the incidence of residual neuromuscular blockade, and

        -  the timing of reversal of the neuromuscular blockade at the end of anaesthesia.

      We will collect data from 7 Danish anaesthesia departments, using data from the Anaesthesia
      Information Management System (AIMS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</measure>
    <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
    <description>The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively</measure>
    <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With and Without Mild Oxygen Desaturation (&lt;90%, But &gt;80%) in Cases Receiving a Non-depolarizing NMBA</measure>
    <time_frame>in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With and Without Severe Oxygen Desaturation (&lt;80%) in Cases Receiving a Non-depolarizing NMBA</measure>
    <time_frame>in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30430</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Eligible patients</arm_group_label>
    <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Succinylcholine</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisatracurium</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mivacurium</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Objective neuromuscular monitoring (acceleromyography)</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <arm_group_label>Eligible patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received general anaesthesia with neuromuscular blockade
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who received general anaesthesia with neuromuscular blockade in one of the 7
        hospitals providing data for the study in the last 18 months up until the time of data
        collection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob L Thomsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sponsor principal investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>May 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2019</results_first_posted>
  <last_update_submitted>August 3, 2019</last_update_submitted>
  <last_update_submitted_qc>August 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Jakob Louis Thomsen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Residual nerve blockade</keyword>
  <keyword>Neuromuscular monitoring</keyword>
  <keyword>Residual curarization</keyword>
  <keyword>Neuromuscular blocking agents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Mivacurium</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of data not included in the permissions granted by authorities stated below</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02914119/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02914119/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Estimated number of included cases</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eligible Patients</title>
          <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eligible Patients</title>
          <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30430"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30430"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16920"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)</title>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
        <population>Patients receiving non-depolarizing neuromuscular blocking agent</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no)</title>
          <population>Patients receiving non-depolarizing neuromuscular blocking agent</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Monitoring applied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Monitoring not applied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no)</title>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
        <population>Patients receiving succinylcholine only</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no)</title>
          <population>Patients receiving succinylcholine only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Monitoring applied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Monitoring not applied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</title>
        <description>The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation.</description>
        <time_frame>in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA</title>
          <description>The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation.</description>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Train-of-four ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.90" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13090"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 5 hours</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no)</title>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8570"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively</title>
        <time_frame>in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively</title>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="63" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With and Without Mild Oxygen Desaturation (&lt;90%, But &gt;80%) in Cases Receiving a Non-depolarizing NMBA</title>
        <time_frame>in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Mild Oxygen Desaturation (&lt;90%, But &gt;80%) in Cases Receiving a Non-depolarizing NMBA</title>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15983"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Desaturation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1753"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No desaturation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With and Without Severe Oxygen Desaturation (&lt;80%) in Cases Receiving a Non-depolarizing NMBA</title>
        <time_frame>in the period between tracheal extubation or removal of supraglottic airway device and discharge from post-anaesthesia care unit, assessed up to 24 hours</time_frame>
        <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Eligible Patients</title>
            <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With and Without Severe Oxygen Desaturation (&lt;80%) in Cases Receiving a Non-depolarizing NMBA</title>
          <population>Only participants with data on the outcome was analyzed, as per protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15983"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Desaturation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No desaturation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Averse events data were not collected for the study because it was a retrospective database study. Adverse events were collected and reported by individual institutions according to local procedure.</time_frame>
      <desc>Averse events data were not collected for the study because it was a retrospective database study. Adverse events were collected and reported by individual institutions according to local procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Eligible Patients</title>
          <description>Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.
Rocuronium
Succinylcholine
Cisatracurium
Mivacurium
Objective neuromuscular monitoring (acceleromyography)
Sugammadex
Neostigmine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. JLD Thomsen</name_or_title>
      <organization>Herlev Hospital, research unit, anesthesia</organization>
      <phone>004538633863</phone>
      <email>prs@demants.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

